Profile data is unavailable for this security.
About the company
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
- Revenue in DKK (TTM)76.87m
- Net income in DKK-1.05bn
- Incorporated1997
- Employees298.00
- LocationZealand Pharma A/SSydmarken 11SOEBORG 2860DenmarkDNK
- Phone+45 88773600
- Fax+45 88773898
- Websitehttps://www.zealandpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gubra A/S | 223.82m | -46.53m | 9.91bn | 235.00 | -- | 21.30 | -- | 44.27 | -2.82 | -2.82 | 13.54 | 28.44 | 0.3627 | -- | 8.07 | 1,021,986.00 | -7.54 | -- | -8.33 | -- | 58.74 | -- | -20.79 | -- | -- | -- | 0.1647 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Galapagos NV | 2.26bn | -452.07m | 11.78bn | 683.00 | -- | 0.5516 | -- | 5.20 | -0.9096 | 3.14 | 4.61 | 43.44 | 0.0704 | 0.3157 | 6.58 | 470,055.70 | -1.41 | -1.48 | -1.55 | -1.65 | 65.10 | -- | -19.96 | -14.42 | 9.95 | -- | 0.004 | -- | 3.47 | -2.02 | 94.42 | -- | 7.04 | -- |
| Evotec SE | 5.80bn | -1.28bn | 13.34bn | 5.01k | -- | 1.84 | -- | 2.30 | -0.9668 | -0.9668 | 4.39 | 5.46 | 0.3661 | 19.82 | 5.22 | 153,537.30 | -8.07 | -0.0064 | -9.86 | -0.0076 | 13.70 | 24.51 | -22.05 | -0.0178 | 1.99 | -3.11 | 0.3268 | 0.00 | 3.99 | 15.79 | 52.23 | -- | 50.62 | -- |
| BB BIOTECH AG | 2.17bn | 1.01bn | 15.99bn | -- | 15.84 | 0.8843 | -- | 7.36 | 2.27 | 2.27 | 4.95 | 40.66 | 0.1077 | -- | -- | -- | 4.99 | 2.34 | 5.64 | 2.52 | 97.86 | 99.06 | 46.32 | 35.40 | -- | 2.17 | 0.1096 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
| BACHEM HOLDING AG | 4.64bn | 911.99m | 42.04bn | 2.01k | 45.94 | 4.01 | 32.48 | 9.06 | 1.52 | 1.52 | 7.71 | 17.42 | 0.3585 | 1.06 | 4.33 | 288,020.40 | 7.05 | 8.85 | 8.10 | 10.28 | 31.04 | 31.63 | 19.66 | 19.74 | 1.57 | 100.82 | 0.0002 | 55.37 | 8.57 | 15.37 | 11.10 | 19.12 | 50.88 | 7.78 |
| Zealand Pharma A/S | 76.87m | -1.05bn | 49.50bn | 298.00 | -- | 5.54 | -- | 643.99 | -16.69 | -16.69 | 1.21 | 125.74 | 0.013 | 3.73 | 0.2625 | 303,834.00 | -17.83 | -42.74 | -18.63 | -50.24 | 72.06 | 96.13 | -1,369.25 | -464.66 | 35.49 | -- | 0.042 | -- | 229.65 | 55.27 | 27.12 | -- | 42.53 | -- |
| Qiagen NV | 14.00bn | 661.84m | 67.50bn | 5.90k | 103.24 | 2.65 | 31.36 | 4.82 | 0.3896 | 0.3896 | 8.40 | 15.17 | 0.3229 | 2.03 | 5.71 | 314,627.40 | 1.53 | 5.41 | 1.77 | 6.53 | 62.73 | 64.65 | 4.73 | 16.35 | 1.89 | -- | 0.3523 | -- | -8.23 | 5.53 | -19.35 | 12.38 | 1.55 | -- |
| Genmab A/S | 19.76bn | 4.64bn | 95.79bn | 2.64k | 20.28 | 2.88 | 32.23 | 4.85 | 71.38 | 71.38 | 303.48 | 502.60 | 0.5277 | 10.98 | 3.37 | 8,966,878.00 | 12.39 | 17.43 | 13.76 | 18.59 | 96.08 | -- | 23.47 | 35.87 | 5.15 | -- | 0.03 | -- | 13.57 | 40.35 | -20.18 | 24.21 | -4.66 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Polar Capital LLPas of 19 Oct 2023 | 5.65m | 7.95% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 3.54m | 4.99% |
| J.O. Hambro Capital Management Ltd.as of 11 Jan 2024 | 3.13m | 4.40% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.29m | 3.22% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.84m | 2.59% |
| Schroder Investment Management Ltd.as of 31 Aug 2024 | 1.49m | 2.11% |
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 1.48m | 2.09% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 1.21m | 1.71% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 1.13m | 1.59% |
| TIAA-CREF Investment Management LLCas of 30 Sep 2024 | 929.79k | 1.31% |
